Abstract: Certain embodiments of the present disclosure provide liquid pharmaceutical formulations, suitable for oral administration, that contain an amount of a tafamidis of from 0.5 mg/ml to 20 mg/ml, water, and an amount of an alkaline pH modifier that yields a content of the tafamidis solubilized in the water of from 0.5 mg/ml to 19.8 mg/ml.

Abstract: The invention relates to a system (10) for dispensing a product, comprising a dispenser that can house at least two cartridges, each of which includes a reservoir containing a base product, a first base product comprising at least 0.1 wt.-% particles having a density differential relative to the medium containing same, preferably of at least 0.5 g/cm3, in particular particles having a density greater than or equal to 2 g/cm3, and a thickening agent. The dispenser allows at least two base products to be dispensed in adjustable proportions, the viscosity of the first base product being preferably greater than 2 Pa·s and more preferably greater than or equal to 4 Pa·s.

Abstract: The invention relates to a system (10) for dispensing a product, comprising a dispenser that can house at least two cartridges, each of which includes a reservoir containing a base product, a first base product comprising at least 0.1 wt.-% particles having a density differential relative to the medium containing same, preferably of at least 0.5 g/cm3, in particular particles having a density greater than or equal to 2 g/cm3, and a thickening agent. The dispenser allows at least two base products to be dispensed in adjustable proportions, the viscosity of the first base product being preferably greater than 2 Pa·s and more preferably greater than or equal to 4 Pa·s.

Abstract: The present invention relates to an ethanol foam sclerosing agent for vascular anomalies and a preparation method thereof. The ethanol foam sclerosing agent includes absolute ethanol, water, Tween 80 and a stabilizer. The ethanol foam sclerosing agent further includes hyaluronic acid. The mass composition of the ethanol foam sclerosing agent includes 32-42% of absolute ethanol, 0.5-2% of Tween 80, 0-25% (excluding 0) of egg yolk lecithin, 0-2% (excluding 0) of hyaluronic acid, and the balance of water. The stabilizer is hyaluronic acid or glycerin. Foam is prepared by the Tessari method. While the original therapeutic effect of ethanol is not changed, the side effect of the ethanol is significantly reduced.

Abstract: Compositions for treating inflammatory skin conditions are described. The compositions can include povidone iodine in aqueous solution, hydrocortisone, diphenhydramine, an emulsifier, and a hydrophobic carrier, where the povidone iodine aqueous solution is emulsified in the hydrophobic carrier. A method of preparing a composition is also described. The method can include adding an aqueous solution of povidone iodine to a hydrophobic carrier, and adding an emulsifier to the hydrophobic carrier at a concentration that emulsifies the aqueous solution of povidone iodine in the hydrophobic carrier upon mixing.

Abstract: The present invention relates to pharmaceutical compositions comprising Akt protein kinase inhibitors with therapeutic activity against diseases such as cancer as well as processes for their preparation and their use as medicament.

Abstract: Disclosed is a pharmaceutically-acceptable composition in the form of a solid, amorphous, mono-particulate powder comprising a mixture of: (a) a pharmacologically-effective dosage amount of an adrenergic receptor modulator, or a pharmaceutically-acceptable salt thereof; and (b) a pharmaceutically-acceptable carrier material, which carrier material comprises a maltodextrin with a dextrose equivalent (DE) that is above 15. Compositions are suitable for transmucosal drug delivery, including nasal delivery, by which said compositions may be loaded into a single-use nasal applicator. Compositions are preferably made by way of spray drying and may further include a disaccharide, such as lactose or trehalose which, along with the active ingredient and maltodextrin, may be spray-dried together in combination. Compositions may further comprise one or more alkyl saccharides. Preferred alkyl saccharides include sucrose esters, such as sucrose monolaurate.

Abstract: A therapeutic composition and a method of producing it by light-activating hypericin in a carrier or solvent. Preferably, the composition is made by combining dried flowers and/or flower stems of St. John's Wort with edible oil and exposing the mixture to the sun for a prolonged time. This process serves to light-activate the hypericin before its use and reduce risk of skin phototoxicity. The composition can be used for treating undesirable conditions such as mouth sores and vaginal infections.

Abstract: The present disclosure relates to a pharmaceutical composition having a mixture containing curcuminoids as at least one of the active therapeutic agents. Generally, the mixture comprises 4-8% by weight of purified curcuminoids; 20-35% by weight of an oil phase; 25-35% by weight of a co-solvent; and 40-50% by weight of a surfactant. Preferably, the purified curcuminoids in the mixture has an average size of about 19 nm or at least half of the curcuminoids carried in the mixture has particle size not exceeding 19 nm.

Abstract: Disclosed herein are pharmaceutical compositions in the form of a suspension for oral delivery. Some embodiments provide a pharmaceutical composition in the form of a suspension for oral delivery comprising an active pharmaceutical ingredient; water; a suspending agent; a buffering agent; and one or more of a wetting agent and a binder/filler. In some embodiments, the active pharmaceutical ingredient is selected from quetiapine, sildenafil, tadalafil, cinacalcet, ticagrelor, mycophenolate, aprepitant, zonisamide, and primidone.

Abstract: The present disclosure provides a magnetic dressing and a preparation method and use thereof, belonging to the technical field of pharmaceutical preparations. The magnetic dressing includes a magnetic layer, a drug-loading layer, and a protective layer that are stacked in sequence, where the magnetic layer includes polyvinyl alcohol, gluten, and iron particles. In the present disclosure, a swallowed magnetic dressing is controlled by an external magnetic field, and the magnetic dressing is moved to a pathological position by changing a direction of the external magnetic field; after the external magnetic field is removed, the magnetic dressing changes from a ring to a sheet, thereby completing attachment of an entire lesion surface to complete treatment by autonomous drug release.

Abstract: The present invention is in the field of antioxidants and relates to cosmetic or pharmaceutical, preferably dermatological, compositions or homecare product comprising or consisting of a synergistic combination of a specific antioxidant and an effective amount of 1,2-heptanediol and/or 2,3-heptanediol or of a specific alkanediol or a mixture of two or more different specific alkanediols and the use of said compositions as a cosmetic, for personal care, as a pharmaceutical or homecare product, in particular for scavenging reactive oxygen species (ROS), for inhibition matrix metalloproteinases expression and/or for inhibiting interleukin 8 (IL-8) secretion.

Abstract: The present disclosure provides compounds useful as inhibitors of SARM1 NADase activity, compositions thereof, and methods of using the same. The present disclosure provides compounds useful for treating a neurodegenerative or neurological disease or disorder, compositions thereof, and methods of using the same.

Abstract: A device, comprising a base, and a plurality of microneedles attached to the base, wherein the microneedles comprise dehydrated honey having water content of less than 5% by weight. The dehydrated honey can be a Manuka dehydrated honey. Also disclosed are methods of fabricating and using the disclosed device.

Abstract: This invention refers to a formulation comprising at least one medicinal plant, part or extract of it, one or more extracting agents and one or more pharmaceutically or cosmetically acceptable excipients that generate a plant extract (plant derivative) with a high bioactive content for regeneration of the skin, dermal mucous membrane and related parts, used as an active pharmaceutical ingredient to treat wounds of any kind or as a cosmetic ingredient for protection, maintenance and natural balance of the skin, dermal mucous membrane and related parts. The use of this formulation generates pharmaceutical products of high efficacy, of topic used, which provide treatments of low cost, reduced time and of less complexity of the procedures by the healthcare professionals, intended to the treatment of chronic and acute lesions of the skin, dermal mucous membrane and related parts.

Abstract: Provided herein are photodynamic compositions that can contain a natural polymer scaffold and a photosensitizer, where the photosensitizer can be covalently or non-covalently attached to the natural polymer scaffold. Also provided herein are structures and objects that can contain the photodynamic compositions. Further provided herein are methods of making and using the photodynamic compositions. Finally provided herein are printing ink formulations.

Abstract: The extract of Agathis robusta as an antifungal agent is prepared by hydrodistillation of the powdered bark of A. robusta in a Clevenger-type apparatus at 100° C. for 6 hours to obtain the essential oils of A. robusta. The essential oil is mixed with an ointment base of cholesterol, liquid paraffin, lanolin, and vaseline album, the powdered essential oil of A. robusta being added to the ointment base at 1 or 2% w/w and homogenized to a smooth ointment. When tested in vivo on Wistar rats topically infected with Candida albicans, both the 1% and 2% ointment formulations demonstrated substantial antifungal activity.

Abstract: Particles, compositions, and methods that aid particle transport in mucus are provided. The compositions and methods may include, in some embodiments, modifying the surface coatings of particles including pharmaceutical agents that have a low water/aqueous solubility. In some embodiments, a surface coating includes a synthetic polymer having pendant hydroxyl groups on the backbone of the polymer, such as poly(vinyl alcohol) (PVA). Such compositions and methods can be used to achieve efficient transport of particles of pharmaceutical agents though mucus barriers in the body for a wide spectrum of applications, including drug delivery, imaging, and diagnostic applications. In certain embodiments, a pharmaceutical composition including such particles is well-suited for administration routes involving the particles passing through a mucosal barrier.

Abstract: Solid oral dosage forms containing 325 mg of acetaminophen and 97.5 mg of ibuprofen or 500 mg of acetaminophen and 150 mg of ibuprofen, wherein the ibuprofen has a [D50] between 1 and 9 ?m, are described.

Abstract: Method of mitigating or reversing the effect of alopecia comprising applying select aryl alkanones to those areas of the skin suffering hair thinning and/or loss.